We read with great interest the letter by Marchiò et al.
(1) on our recently published paper describing the rational design and testing of a vaccine directed against the major angiogenic growth factor VEGF (2). The letter raises the concern that the potential of the vaccine is limited because of the anaphylactic responses observed in the active vaccination experiments in mice and the incomplete tumor responses observed. The adverse effects observed were most likely because of the high antigen dose (10 mg/kg per immunization) used in the mouse studies. Rats treated with much lower doses (0.5 mg/kg per immunization) lacked such adverse responses. Similarly, extensive studies in cynomolgus monkeys demonstrated the vaccine to be safe. Furthermore, the phase I clinical study is currently going on and safety issues do not present, although conclusions about efficacy in patients cannot yet be drawn. We are looking forward to a successful clinical development and welcome a substantial improvement of overall survival, even if a full control of tumor growth, with the vaccine only, is not yet offered.
With even greater interest, we read the suggestion by Marchiò et al.
(1) that a targeted approach against VEGF could, besides the prevention of pathological neoangiogenesis, contribute to the release of the tumor-mediated immune suppression. This notion is of extreme importance because it has become clear that releasing immune suppression has shown the capacity to induce long-term patient survivals and supposed cures. Indeed, it has been shown that VEGF is an immunosuppressive factor. This is obvious from many studies indicating inadequate antigen presentation by dendritic cells, deviated maturation of macrophages, and appearance of regulatory T lymphocytes (3), leading to immune suppression and proangiogenic conditions. Furthermore, this immunosuppressive tumor microenvironment is a general feature in cancer, as we have demonstrated that a tumor escapes from immunity by switching on the process of angiogenesis. This results in the selective suppression of endothelial adhesion molecules involved in leukocyte infiltration, such as intercellular and vascular cell adhesion molecules (ICAMs, VCAMs) as well as selectins, a process referred to as tumor endothelial cell anergy, revealing the tumor as an immunocompromised area (4, 5) . We fully agree with Marchiò et al. (2) that intervention in these phenomena by angiostatic strategies will help to get the tumor more vulnerable to immunity (6), as we have previously shown in preclinical models (7, 8) .
The most urgent question for now is how to tackle the problem of the immunosuppressive environment most efficiently. We definitely agree that this may be done by vaccination procedures directed against proangiogenic regulators or by targeting approaches against markers of the tumor vasculature: for example, by the described anti-VEGF vaccine (2), or alternatively by antibody inducing conjugate vaccines against proteins marking the tumor vasculature (9, 10) . Both strategies will combine the angiostatic activity with a boost of the antitumor immunity. Using the fingerprinting technology to identify tumor targets by finding tumor-directed antibodies in patient sera (11) , especially the ones to appear in patients upon regression of the tumor, is most intriguing and should be followed up as soon as possible.
